ABCL AbCellera Biologics Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
18:40
Jul 12
Jul 12
Named in a health sector thematic basket the author describes as areas of value they are rotating across.
MED
16:55
Jul 02
Jul 02
Speaker replies with ticker and handshake emoji, implying agreement with biotech longs but no mechanism or reason.
LOW
13:00
Jun 30
Jun 30
Author names ABCL as a short-term favorite pick when asked to choose among five names; very low conviction, hedged with "maybe," no catalyst provided.
LOW
11:56
Jun 30
Jun 30
Speaker presents this as a top pick with bullish catalysts (Jazz collab, interim data, wave pattern), no personal position stated.
MED
22:15
Jun 29
Jun 29
Reports that Citrini has taken a position in ABCL, no directional view from speaker.
MED
16:34
Jun 29
Jun 29
Author discloses current high-conviction long position in ABCL, citing ongoing re-rating with near-term momentum and significant upside potential.
MED
14:02
Jun 29
Jun 29
Buy ABCL on re-rating catalyst from resolved IP litigation, fortress balance sheet, insider buying, and partnerships with $LLY; trading near book value.
HIGH
10:27
Jun 29
Jun 29
Author expresses love for ABCL and VKTX with bullish commentary on potential and chart, but no explicit position language or forward call, so both are watch.
LOW
14:40
Jun 27
Jun 27
Listed as part of thematic sector overview in author's market read, no directional view expressed.
LOW
23:03
Jun 23
Jun 23
Named as one of author's preferred health/bio sector picks in a multi-theme favorite-stocks list backed by personal research.
MED
00:38
Jun 21
Jun 21
Author asks if the recipient has looked into VKTX or ABCL, a research inquiry without a directional position or endorsement.
LOW
15:52
Jun 20
Jun 20
The author shares their favorite biotech stocks with AI-driven drug discovery and gene editing platforms but frames them as personal favorites without an explicit forward-looking position or trade call.
LOW
10:59
Jun 18
Jun 18
Mentions Abcl as a 2-3 year hold, but no directional thesis or catalyst provided.
LOW
10:44
Jun 18
Jun 18
Buy ABCL as part of an AI-augmented biotech basket; author explicitly names it as one of their personal bets on the AI-meets-biology convergence theme.
MED
09:04
Jun 10
Jun 10
The author presents a large diversified basket of favorite names across sectors as where they are positioned for the next few years, but the 30+ tickers default to watch due to the basket size rule.
22:25
Jun 09
Jun 09
The author is asking about ABCL with an eye emoji in response to a vague bullish parent post, but no explicit position or forward call is stated.
LOW
17:37
Jun 09
Jun 09
Author discloses current positioning in ABCL as a Health name, framing the dip as a buying opportunity with a multi-year hold thesis.
MED
08:37
Jun 08
Jun 08
Author provides a broad thematic basket of strong buy and buy ratings with enablers/beneficiaries framing, explicitly recommends selling Carvana, but the large list defaults to watch except for the explicit sell call on CVNA.
LOW
23:13
Jun 05
Jun 05
Author lists ABCL in a health/biotech basket with a blanket current-holdings disclosure; thematic basket per speaker note, no ticker-specific thesis.
LOW
10:01
Jun 05
Jun 05
Speaker cites ABCL as a fundamentals benchmark superior to RXRX in a comparative thesis; no explicit directional commitment on ABCL itself.
MED
15:42
Jun 04
Jun 04
Author identifies ABCL as a proteonomics/AI antibody stock moving in the biotech sector, no directional view.
LOW
15:02
Jun 04
Jun 04
Author states they are long ABCL and QS long term while discussing a short-term full port trade on another ticker.
14:58
Jun 04
Jun 04
The author expresses mild interest in ABCL, OUST, and ADYS but uses hedged language ("we'll see", "I like...here too") without a forward-looking position or explicit ownership.
LOW
14:55
Jun 04
Jun 04
Author evaluates three biotech tickers as potential long-term holds depending on clinical data, explicitly ruling out ABSI, but offers no personal position or forward call.
LOW
14:50
Jun 04
Jun 04
Author reiterates a prior bullish biotech thesis from research discord but provides no current position disclosure or forward directional call in the tweet itself.
00:56
Jun 02
Jun 02
Author explicitly says ABSI, ABCL, and IOVA are their bets on the digital biology narrative, which they expects to run hard.
MED
20:23
Jun 01
Jun 01
Author confirms trimming one position to rotate into ABCL, ASYS, ZETA, and RDDT as new plays with more room to grow.
15:42
Jun 01
Jun 01
Buy ABCL ahead of Q3 2026 Phase 2 efficacy readout for ABCL635 (non-hormonal menopausal hot flash treatment); Phase 1 showed clean liver-safety profile, Baker Bros. holds 10%, ~20% short interest creates squeeze potential, and stock is breaking out of a 2-year cup-and-handle on the weekly chart.
MED
18:12
May 29
May 29
Author discloses current long positions in ABCL and ABSI as plays on the "digital biology" / AI-augmented personalized medicine theme, expecting the sector to become a major category within five years.
MED
23:54
May 26
May 26
ABCL is a buy at current levels with acknowledged downside risk to mid-$4s; author recommends DCA or tranched entry to manage volatility rather than a single full position.
MED
About ABCL Analyst Coverage
Buzzberg tracks ABCL (AbCellera Biologics Inc.) across 4 sources. 21 bullish vs 0 bearish calls from 6 analysts. Sentiment: predominantly bullish (49%). 43 total trade ideas tracked. Latest voices: __con_, CryptoCondom, moninvestor.